These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 20584580)
1. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer. Scheer RV; Fakiris AJ; Johnstone PA Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):996-1001. PubMed ID: 20584580 [TBL] [Abstract][Full Text] [Related]
2. En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma. Rizzetto C; DeMeester SR; Hagen JA; Peyre CG; Lipham JC; DeMeester TR J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1228-36. PubMed ID: 18544359 [TBL] [Abstract][Full Text] [Related]
3. Do elderly patients experience increased perioperative or postoperative morbidity or mortality when given neoadjuvant chemoradiation before esophagectomy? Fogh SE; Yu A; Kubicek GJ; Scott W; Mitchell E; Rosato EL; Berger AC Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1372-6. PubMed ID: 21106309 [TBL] [Abstract][Full Text] [Related]
4. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576 [TBL] [Abstract][Full Text] [Related]
5. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Kim MP; Correa AM; Lee J; Rice DC; Roth JA; Mehran RJ; Walsh GL; Ajani JA; Maru DM; Chang JY; Marom EM; Macapinlac HA; Lee JH; Vaporciyan AA; Rice T; Swisher SG; Hofstetter WL Ann Thorac Surg; 2010 Sep; 90(3):884-90; discussion 890-1. PubMed ID: 20732513 [TBL] [Abstract][Full Text] [Related]
6. [New trends in neoadjuvant chemoradiotherapy for locally-advanced esophageal cancer: esophagectomy--is it necessary?]. Fujita H; Sueyoshi S; Tanaka T; Toh U; Mine T; Sasahara H; Shirouzu K; Yamana H; Toda Y; Hayabuchi N Gan To Kagaku Ryoho; 2000 Nov; 27(13):2016-22. PubMed ID: 11103231 [TBL] [Abstract][Full Text] [Related]
7. Outcomes after trimodality therapy for esophageal cancer: the impact of histology on failure patterns. Koshy M; Greenwald BD; Hausner P; Krasna MJ; Horiba N; Battafarano RJ; Burrows W; Suntharalingam M Am J Clin Oncol; 2011 Jun; 34(3):259-64. PubMed ID: 20686405 [TBL] [Abstract][Full Text] [Related]
8. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. Kim DW; Blanke CD; Wu H; Shyr Y; Berlin J; Beauchamp RD; Chakravarthy B Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):397-404. PubMed ID: 17097833 [TBL] [Abstract][Full Text] [Related]
10. Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study. Schwer AL; Ballonoff A; McCammon R; Rusthoven K; D'Agostino RB; Schefter TE Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):449-55. PubMed ID: 18538500 [TBL] [Abstract][Full Text] [Related]
11. The effectiveness of planned esophagectomy after neoadjuvant chemoradiotherapy for advanced esophageal carcinomas. Kato H; Fukuchi M; Manda R; Faried A; Takita J; Nakajima M; Miyazaki T; Sohda M; Fukai Y; Masuda N; Tsukada K; Kuwano H Anticancer Res; 2004; 24(6):4091-6. PubMed ID: 15736457 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: experience at a single institution. Malaisrie SC; Untch B; Aranha GV; Mohideen N; Hantel A; Pickleman J Arch Surg; 2004 May; 139(5):532-8; discussion 538-9. PubMed ID: 15136354 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer. Luu TD; Gaur P; Force SD; Staley CA; Mansour KA; Miller JI; Miller DL Ann Thorac Surg; 2008 Apr; 85(4):1217-23; discussion 1223-4. PubMed ID: 18355499 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients. Samson P; Robinson C; Bradley J; Lockhart AC; Puri V; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T J Thorac Oncol; 2016 Dec; 11(12):2227-2237. PubMed ID: 27544058 [TBL] [Abstract][Full Text] [Related]
15. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report. Henry LR; Goldberg M; Scott W; Konski A; Meropol NJ; Freedman G; Weiner LM; Watts P; Beard M; McLaughlin S; Cheng JD Ann Surg Oncol; 2006 Feb; 13(2):214-20. PubMed ID: 16418887 [TBL] [Abstract][Full Text] [Related]
16. Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer. Nakamura T; Hayashi K; Ota M; Eguchi R; Ide H; Takasaki K; Mitsuhashi N Am J Surg; 2004 Sep; 188(3):261-6. PubMed ID: 15450831 [TBL] [Abstract][Full Text] [Related]
18. Preoperative therapy for esophageal cancer. Ku GY; Ilson DH Gastroenterol Clin North Am; 2009 Mar; 38(1):135-52, ix. PubMed ID: 19327572 [TBL] [Abstract][Full Text] [Related]
19. [Pathologic complete response of thoracic esophageal cancer developing after gastrectomy to neoadjuvant low-dose nedaplatin (CDGP), 5-fluorouracil and radiotherapy]. Takemura M; Osugi H; Lee S; Nishikawa T; Fukuhara K; Iwasaki H Gan To Kagaku Ryoho; 2005 Jul; 32(7):1023-7. PubMed ID: 16044966 [TBL] [Abstract][Full Text] [Related]
20. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy. Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]